FINWIRES · TerminalLIVE
FINWIRES

$ENGN

8 stories mentioning ENGNUpdated 50m ago

Every FINWIRES story that references ENGN, newest first.

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Thursday afternoon with the NYSE Healthcare Index dropping 1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.9%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, Pfizer (PFE) shares dropped 2.5% after the company reaffirmed its fiscal 2026 guidance. The company also said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 1.4%.EnGene (ENGN) shares shed 1.4% after Morgan Stanley downgraded the stock to underweight from equalweight.NovoCure (NVCR) shares tumbled 19% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.

$BIIB$ENGN$NVCR$PFE
Wire

EnGene Shares Fall After Morgan Stanley Downgrade

EnGene (ENGN) shares fell 1.4% in Thursday trading after Morgan Stanley downgraded the stock to underweight from equalweight.Trading volume stood at over 735,000 shares compared with a daily average of nearly 1.6 million.Price: $1.72, Change: $-0.02, Percent Change: -1.44%

$ENGN
Research

Guggenheim Downgrades enGene Holdings to Neutral From Buy

enGene Holdings (ENGN) has an average rating of overweight and mean price target of $11.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ENGN
Research

Morgan Stanley Downgrades enGene Holdings to Equalweight From Overweight

enGene Holdings (ENGN) has an average rating of overweight and mean price target of $11.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ENGN
Research

Wells Fargo Downgrades enGene Holdings to Equalweight From Overweight

enGene (ENGN) has an average rating of overweight and mean price target of $11.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ENGN
Research

Oppenheimer Downgrades enGene Holdings to Market Perform From Outperform

enGene Holdings (ENGN) has an average rating of overweight and mean price target of $11.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ENGN
Research

Citizens Downgrades enGene to Market Perform From Market Outperform

enGene (ENGN) has an average rating of overweight and mean price target of $11.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ENGN
Research

Piper Sandler Downgrades enGene Holdings to Neutral From Overweight, Adjusts Price Target to $4 From $7

enGene Holdings (ENGN) has an average rating of overweight and mean price target of $11.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ENGN

Track with the FINWIRES app suite